Gleevec, a new medicine for leukemia, to be sold in June.
Having held a Central Medical Council on May 31, the Korea Food and Drug Administration (KFDA) formed a conclusion that Gleevec should be designated as an orphan drug.
According to this, K...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
